Longevity: Can We Add Another 30 Years? | The Decade Ahead

People are living longer than ever before and the science helping us live healthier for longer is advancing at a rapid pace. From AI-powered drug discovery and personalised medicine to GLP-1s and the longevity economy, this episode explores the trends reshaping healthcare, the companies leading the charge, and how investors can gain exposure to one of the world's fastest-growing industries.

In this episode:
00:00 – Why longevity is becoming a major investment theme
03:16 – The $3.5 trillion biotech opportunity & the rise of the longevity economy
07:58 – AI, peptides & personalised medicine driving medical breakthroughs
14:56 – The risks: regulation, clinical trial failures & tariffs
17:47 – Partner message from ANZ Business Start Right
19:22 – The biggest opportunities in biotech over the next decade
20:25 – The companies leading the biotech revolution
27:13 – ETFs and how to invest in Biotech & Longevity

Stocks & ETFs Mentioned: CSL (ASX: CSL), Pfizer (NYSE: PFE), Merck (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Roche, AstraZeneca (LSE: AZN), AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Vertex Pharmaceuticals (NASDAQ: VRTX), Regeneron Pharmaceuticals (NASDAQ: REGN), Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), Unity Biotechnology (NASDAQ: UBX), BioAge Labs (NASDAQ: BIOA), Recursion Pharmaceuticals (NASDAQ: RXRX), ResMed (ASX: RMD), Cochlear (ASX: COH), Sonic Healthcare (ASX: SHL), Pro Medicus (ASX: PME), Telix Pharmaceuticals (ASX: TLX), Mesoblast (ASX: MSB), VanEck Global Healthcare Leaders ETF (ASX: HLTH), iShares Global Healthcare ETF (ASX: IXJ), Betashares Global Healthcare Currency Hedged ETF (ASX: DRUG), iShares U.S. Pharmaceuticals ETF, iShares Biotechnology ETF (NYSEARCA: IBB), SPDR S&P Biotech ETF (NYSEARCA: XBI), ARK Genomic Revolution ETF (BATS: ARKG), Range Cancer Therapeutics ETF (CANC)

This episode ofThe Decade Ahead is brought to you by ANZ Business Start Right anz.com.au/business/business-hub/starting-busi…

———

Want to get involved in the podcast? Record a voice note (tinyurl.com/4uw5f58j) or send us a message (tinyurl.com/2hyfsrw7)

And come and join the conversation in the Equity Mates Facebook Discussion Group (facebook.com/groups/equitymates).

———

Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we’ve got you covered (linktr.ee/equitymates).

Keep up with the news moving markets with our daily newsletter (tinyurl.com/2saau2ky) and podcast (Apple (tinyurl.com/yxm3mm2c) | Spotify (tinyurl.com/299dedpd))

We’re particularly excited to share our latest show: Basis Points

Listen to the podcast (Apple (tinyurl.com/2zmumf7v) | Spotify (tinyurl.com/mr4x8tae))

Watch on YouTube (tinyurl.com/yc596wem)

Read the monthly email (basispoints.beehiiv.com)

———

Looking for some of our favourite research tools?
Download our free Basics of ETF handbook (tinyurl.com/7k2z7ebx)
Or our free 4-step stock checklist (tinyurl.com/4zjkm3pt)
Find company information on TIKR (tikr.com/?ref=equitymates)
Research reports from Good Research (goodresearch.com.au/ref/equitymates)
Track your portfolio with Sharesight (sharesight.com/au/equitymates)

———

This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697.
Hosted on Acast. See acast.com/privacy for more information.